ClinicalTrials.gg
RecruitingNCT07193810Updated Apr 14, 2026

A Study of CC312 for Relapsed/Refractory Autoimmune Diseases

An Early Phase 1 interventional study of CC312 in SLE - Systemic Lupus Erythematosus, IIM- Idiopathic Inflammatory Myopathies and SSc-Systemic Sclerosis, sponsored by CytoCares Inc. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by CytoCares Inc · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Planned enrollment
229th of 245
6 · median 36
Started
2025
with 61 others
Phase 1
109 of 266
85 open now
Primary completion
2027-09
later than 112 of 190 live
Registered
195th of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 229th largest by planned enrollment of the 245 interventional ones that give a count, is one of 62 that started in 2025, is one of 109 in phase 1, reaches primary completion later than 112 of the 190 other live ones, and was the 195th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

This study is an open-label, multiple ascending dose investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CC312 in adult patients with relapsed or refractory autoimmune diseases.

03

Conditions studied

  • SLE - Systemic Lupus Erythematosus
  • IIM- Idiopathic Inflammatory Myopathies
  • SSc-Systemic Sclerosis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fully understand the trial's purpose, nature, methodology, and potential adverse reactions, voluntarily participate as a subject, and sign the form.
  • Aged 18-65 years (inclusive, based on the date of signing the informed consent form), regardless of gender.
  • For Systemic Lupus Erythematosus (SLE):

    1. Diagnosed with SLE according to the 2019 EULAR/ACR classification criteria;
    2. Meet at least one of the following: positive antinuclear antibody (ANA) and/or anti-dsDNA antibody and/or anti-Sm antibody at screening;
    3. Had an inadequate response or relapse after standard therapy, defined as any of the following (alone or combined): , antimalarials (hydroxychloroquine), (including mycophenolate mofetil, cyclophosphamide, leflunomide, methotrexate, tacrolimus, cyclosporine, azathioprine), or biologics (rituximab, belimumab, telitacicept). Each regimen must have been administered for ≥3 months, and the subject must have received ≥2 immunosuppressants and/or biologics;
    4. At screening, meet SLEDAI-2000 ≥7 and have at least one BILAG A or two BILAG B organ domain scores;
    5. Prior to the first dose, subjects must have received glucocorticoids and/or antimalarials and/or immunosuppressants for ≥12 weeks, with stable doses for ≥30 days;
    6. If receiving oral glucocorticoids (e.g., prednisone), the dose must be ≤40 mg/day at screening and during the screening period;
    7. If using glucocorticoids alone, the dose must be ≥7.5 mg/day prednisone (or equivalent).
  • For Idiopathic Inflammatory Myopathy (IIM):

    1. Diagnosed with possible or definite IIM per the 2017 EULAR/ACR classification criteria (≥5.5 points without ; ≥6.7 points with biopsy) ;
    2. Have at least one positive myositis-specific autoantibody (MSA) , myositis-associated autoantibody (MAA), or ANA at or prior to screening;
    3. Had an inadequate response or relapse after conventional therapy, defined as glucocorticoids (prednisone >1 mg/kg/day or equivalent) and ≥1 immunomodulatory drug (immunosuppressants: azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine; biologics: rituximab, belimumab; small molecules: tofacitinib), each for ≥3 months;
    4. Have active IIM at screening, defined as meeting ≥3 of MMT-8 total score ≤141/150 with ≥20% strength loss in affected muscles; Physician global activity ≥2; Patient global activity ≥2; myositis disease activity assessment tool (MDAAT) ≥2; ≥2 muscle enzymes elevated, with one ≥1.5× (ULN); health assessment questionnaire (HAQ) ≥0.25;
    5. Prior to the first dose, subjects must have received glucocorticoids and/or immunosuppressants for ≥12 weeks, with stable glucocorticoid doses for ≥30 days and immunosuppressant doses for ≥60 days. Glucocorticoid dose must be ≤60 mg/day prednisone during screening;
    6. If a subject is receiving oral glucocorticoids alone, the dose should be at least 7.5 mg/day of prednisone (or an equivalent dose of other glucocorticoids).
  • For Systemic Sclerosis (SSc):

    1. Diagnosed with diffuse cutaneous SSc per the 2013 EULAR/ACR criteria ;
    2. Have positive ANA and/or SSc-related antibodies;
    3. Disease duration ≤5 years (from initial diagnosis);
    4. Had an inadequate response or relapse after conventional therapy. Conventional therapy is defined as treatment with glucocorticoids plus any of the following immunomodulatory agents: cyclophosphamide, mycophenolate mofetil, methotrexate, leflunomide, azathioprine, tacrolimus, cyclosporine, and/or biologics (such as rituximab and belimumab), with a cumulative treatment duration of >6 months;
    5. Modified Rodnan Skin Score (mRSS) ≥15 and ≤30 at screening with progression within 6 months;
    6. Prior to the first dose, subjects must have received glucocorticoids and/or immunosuppressants for ≥12 weeks, with stable glucocorticoid doses for ≥30 days and immunosuppressant doses for ≥60 days. The glucocorticoid dose during the screening period should not exceed 10 mg/day of prednisone (or an equivalent dose of other glucocorticoids).
  • Females of must use highly effective from screening until 6 months after the last dose, refrain from oocyte donation, and ensure male partners use effective contraception.
  • Males of childbearing potential must use effective contraception from screening until 6 months after the last dose, with no plans for fertility or sperm donation, and ensure female partners use effective contraception.

Exclusion criteria

Exclusion Criteria:

  • Severe lupus nephritis within 8 weeks prior to screening (defined as urinary protein >6 g/24 h, serum creatinine >2.5 mg/dL or 221 μmol/L), requirement of prohibited medications for active nephritis per protocol, need for hemodialysis, or receipt of prednisone ≥100 mg/day (or equivalent ) for ≥14 days.
  • Central nervous system disorders (including but not limited to epilepsy, psychosis, interstitial encephalopathy syndrome, cerebrovascular accident, encephalitis, or CNS vasculitis) within 8 weeks prior to screening.
  • Other types of idiopathic inflammatory myopathies: inclusion body myositis, amyotrophic diabetes, or juvenile myositis; patients with severe muscle damage or permanent weakness/cardiac involvement due to non-IIM causes (e.g., stroke).
  • SSc-related pulmonary hypertension requiring treatment; rapidly progressive SSc-related lower gastrointestinal (small/large intestine) involvement requiring parenteral nutrition; active gastric antral vascular ectasia; history of SSc-related renal crisis.
  • History of major organ transplantation (e.g., heart, lung, kidney, liver) or hematopoietic stem cell/bone marrow transplantation.
  • Other concurrent diseases requiring systemic therapy.
  • IgA deficiency (serum IgA level \<10 mg/dL).
  • Abnormal laboratory findings at screening: Liver function: /ALT >2× (ULN) (except for IIM patients with elevated muscle enzymes); Hematology: \<85 g/L, white blood cell count \<2.5×10⁹/L, count \<50×10⁹/L.
  • Participation in any other clinical trial (including cell or gene therapy) within 4 weeks prior to screening or within 5 half-lives of the product (whichever is longer).
  • Received CAR-T therapy within 6 months prior to screening.
  • Treatment with B-cell-depleting agents (e.g., rituximab, or therapies targeting CD19/CD20/BAFF) within 1 month prior to screening, unless B-cell levels returned to pre-treatment or normal ranges.
  • Received non-standard anti-SLE therapies (e.g., Saphnelo) within 3 months or 5 half-lives of the drug (whichever is longer) prior to screening.
  • Received live/attenuated vaccination within 4 weeks prior to screening or plans to receive such during the trial.
  • Active severe infection requiring antibiotic treatment within 14 days prior to screening.
  • History of Grade 3-4 allergic reaction (per v5.0) to another monoclonal antibody, or known to any component of CC312 (e.g., recombinant proteins, polysorbate 80). Patients with transient (≤24 h) Grade ≤3 reactions may be included after discussion with the investigator.
  • Evidence of drug abuse, substance abuse, or alcohol addiction.
  • Major surgery within 4 weeks or minor surgery within 2 weeks prior to screening; wounds must be fully healed (procedures like catheter placement are excluded).
  • History of cardiovascular events within 6 months prior to screening: (NYHA) Class III/IV heart failure, myocardial infarction, unstable angina, uncontrolled/symptomatic atrial arrhythmia, ventricular arrhythmia, or other cardiac conditions.
  • Any other severe underlying disease (e.g., active gastric ulcer, uncontrolled seizures, cerebrovascular events, GI bleeding, severe coagulation disorders), psychiatric disorder, or social circumstances that may interfere with trial conduct, compliance, or pose high risk per investigator's judgment.
  • Concurrent diagnosed within \<5 years prior to screening.
  • Pregnant or lactating women.
  • Positive serology for (HIV) antibody, Surface Antigen (HBsAg), Virus (HCV) antibody, or Treponema pallidum (TP) antibody at screening.
  • Active or latent tuberculosis at screening (positive TB-IGRA test).
  • Any other condition deemed ineligible by the investigator.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    CC312

    Biological: CC312

Interventions

  • BiologicalCC312

    The priming dose of CC312 will be administered intravenously on Day -3, followed by safety and tolerability evaluations on Day -1 (3 days post-first dose). The first therapeutic dose of CC312 will be administered on Day 1, with subsequent doses administered on Day 4, 8, and 11. Corresponding safety and tolerability assessments will be performed with each dose. Based on the evaluation of clinical efficacy, B-cell depletion, and safety/tolerability profile at the end of Day 14, the dose for the subsequent therapeutic dosing will be determined (maintained or escalated). Thereafter, therapeutic dosing will be administered on Days 15, 18, 22, and 25, accompanied by scheduled safety and tolerability assessments.

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT)

    A Dose-Limiting Toxicity (DLT) is defined as any adverse event occurring within the 29-day period following the initiation of CC312 intravenous infusion during the dose-escalation phase, assessed by the investigator as related to CC312 and meeting the following criteria: (1) Hematologic Toxicity: Grade 4 toxicity (excluding lymphopenia) persisting beyond 29 days and not attributable to underlying disease; (2) Non-Hematologic Toxicity: Any ≥Grade 4 toxicity potentially related to CC312 during the observation window, or any Grade 3 toxicity potentially related to CC312 that fails to resolve to ≤Grade 2 within 7 days.

    Time frame: 2 years

  2. Adverse events (AE)/serious adverse events (SAE)

    With the exception of CRS and ICANS, which will be graded according to the ASTCT criteria, the severity of all other adverse events (AEs) will be assessed and classified using the CTCAE (Common Terminology Criteria for Adverse Events) version 5.0.

    Time frame: 2 years

Secondary outcomes

  1. Serum Concentration of CC312

    All subjects are required to undergo blood sampling for serum concentration analysis at the following time points: within 1 hour before the guide dose (0 h) and 1 hour after infusion; for the treatment dose, within 1 hour before administration (0 h) and 1 hour after infusion on the first and second dosing occasions of the first and third treatment weeks, within 1 hour before administration (0 h) and 1 hour after infusion on the first dosing occasion of the second and fourth treatment weeks; and at early withdrawal/end of study (EOS).

    Time frame: 2 years

  2. Counts of peripheral B cells

    All subjects are required to undergo blood sampling for peripheral B cells analysis at the following time points:within 1 hour before the priming dose (0 h), and 1 hour and 24 hours after infusion; for the treatment dose, within 1 hour before administration (0 h) and 1 hour and 24 hours after infusion on the first and second dosing occasions of Weeks 1 and 3, within 1 hour before administration (0 h) on the first dosing occasions of Week 2 and Week 4; if dosing is extended beyond Day 28, within 1 hour before the second weekly dose until the end of the extended dosing period; after the last dose, once monthly for 4 consecutive months; during the long-term follow-up period, once every 3 months; and at early withdrawal/end of study (EOS).

    Time frame: 2 years

  3. Cytokines

    All subjects are required to undergo blood sampling for cytokine analysis (IFN-γ、IFN-α、IL-2、IL-6、IL-10、TNF-α) at the following time points: within 1 hour before the priming dose (0 h), and 1 hour and 24 hours after infusion; for the treatment dose, within 1 hour before administration (0 h) and 1 hour and 24 hours after infusion on the first and second dosing occasions of Weeks 1 and 3; within 1 hour before administration (0 h) and 1 hour and 24 hours after infusion on the first dosing occasion of Weeks 2 and 4; and at early withdrawal/EOS.

    Time frame: 2 years

  4. Complement

    Blood samples for complement analysis will be collected from all subjects at the following time points: Screening/Baseline, within 1 hour before the priming dose (0 h); for the treatment dose, within 1 hour before the first weekly administration at Weeks 1, 2, 3, and 4, and at Weeks 8, 12, 24, and 48, as well as at early withdrawal.

    Time frame: 2 years

  5. Autoantibody

    For patients with systemic lupus erythematosus, anti-double-stranded DNA antibody (anti-dsDNA) shall be tested at the following time points: within 1 hour before the priming dose (0 h), within 1 hour before the first treatment dose at Week 3, and on Day 28. Other autoantibodies shall be tested at the following time points: within 1 hour before the priming dose (0 h), on Day 28, and at Weeks 8, 12, 24, 48, as well as at early withdrawal.

    Time frame: 2 years

  6. Immunogenicity

    Blood samples for immunogenicity analysis will be collected from all subjects at the following time points: within 1 hour before the priming dose (0 h), and within 1 hour before the first weekly treatment dose at Weeks 1, 2, 3, and 4; as well as at Weeks 8, 12, 16, and 24, and at early withdrawal or end of study (EOS).

    Time frame: 2 years

  7. SLE Responder Index-4 (SRI-4) response rate

    SLE Responder Index-4 (SRI-4) response rate will be assessed at the following time points: during the screening period, at baseline (prior to the first dose), at the end of Week 2 and Week 4, at safety follow-up visits, and at the end of study (EOS). Additionally, during the post-treatment follow-up period, assessments will be conducted every 12 weeks (i.e., at Weeks 12, 24, 36, and 48, respectively).

    Time frame: 2 years

  8. Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score

    SLEDAI-2K score will be assessed at the following time points: during the screening period, at baseline (prior to the first dose), at the end of Week 2 and Week 4, at safety follow-up visits, and at the end of study (EOS). Additionally, during the post-treatment follow-up period, assessments will be conducted every 12 weeks (i.e., at Weeks 12, 24, 36, and 48, respectively).

    Time frame: 2 years

  9. British Isles Lupus Assessment Group Index 2004 (BILAG-2004)

    BILAG-2004 (for SLE patients) will be assessed at the following time points: during the screening period, at baseline (prior to the first dose), at the end of Week 2 and Week 4, at safety follow-up visits, and at the end of study (EOS). Additionally, during the post-treatment follow-up period, assessments will be conducted every 12 weeks (i.e., at Weeks 12, 24, 36, and 48, respectively).

    Time frame: 2 years

  10. 24-hour urinary protein quantification

    24-hour urinary protein quantification (for SLE patients) will be assessed at the following time points: during the screening period, at baseline (prior to the first dose), at the end of Week 2 and Week 4, at safety follow-up visits, and at the end of study (EOS). Additionally, during the post-treatment follow-up period, assessments will be conducted every 12 weeks (i.e., at Weeks 12, 24, 36, and 48, respectively).

    Time frame: 2 years

  11. Physician's and Patient's Global Assessment of disease activity (PGA and PtGA)

    PGA and PtGA (for SLE patients) will be assessed at the following time points: during the screening period, at baseline (prior to the first dose), at the end of Week 2 and Week 4, at safety follow-up visits, and at the end of study (EOS). Additionally, during the post-treatment follow-up period, assessments will be conducted every 12 weeks (i.e., at Weeks 12, 24, 36, and 48, respectively).

    Time frame: 2 years

  12. Total Improvement Score (TIS)

    TIS (for IIM patients) will be assessed at the following time points: during the screening period, at baseline (prior to the first dose), at the end of Week 2 and Week 4, at safety follow-up visits, and at the end of study (EOS). Additionally, during the post-treatment follow-up period, assessments will be conducted every 12 weeks (i.e., at Weeks 12, 24, 36, and 48, respectively).

    Time frame: 2 years

  13. EUSTAR Activity Index (EUSTAR-AI)

    EUSTAR-AI (for SSc patients) will be assessed at the following time points: during the screening period, at baseline (prior to the first dose), at the end of Week 2 and Week 4, at safety follow-up visits, and at the end of study (EOS). Additionally, during the post-treatment follow-up period, assessments will be conducted every 12 weeks (i.e., at Weeks 12, 24, 36, and 48, respectively).

    Time frame: 2 years

  14. modified Rodnan Skin Score (mRSS)

    mRSS (for SSc patients) will be assessed at the following time points: during the screening period, at baseline (prior to the first dose), at the end of Week 2 and Week 4, at safety follow-up visits, and at the end of study (EOS). Additionally, during the post-treatment follow-up period, assessments will be conducted every 12 weeks (i.e., at Weeks 12, 24, 36, and 48, respectively).

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Doria A, Amoura Z, Cervera R, Khamastha MA, Schneider M, Richter J, Guillemin F, Kobelt G, Maurel F, Garofano A, Perna A, Murray M, Schmitt C, Boucot I. Annual direct medical cost of active systemic lupus erythematosus in five European countries. Ann Rheum Dis. 2014 Jan;73(1):154-60. doi: 10.1136/annrheumdis-2012-202443. Epub 2012 Dec 21. PubMed 23264339 ↗
  • Conrad N, Misra S, Verbakel JY, Verbeke G, Molenberghs G, Taylor PN, Mason J, Sattar N, McMurray JJV, McInnes IB, Khunti K, Cambridge G. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023 Jun 3;401(10391):1878-1890. doi: 10.1016/S0140-6736(23)00457-9. Epub 2023 May 5. PubMed 37156255 ↗
  • Karagianni P, Tzioufas AG. Epigenetic perspectives on systemic autoimmune disease. J Autoimmun. 2019 Nov;104:102315. doi: 10.1016/j.jaut.2019.102315. Epub 2019 Aug 15. PubMed 31421964 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 24 months is below that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2025
First posted
Sep 26, 2025
StartActual
Sep 23, 2025
Primary completionEst.
Sep 29, 2027
CompletionEst.
Sep 29, 2027
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07193810
Lead sponsor
CytoCares Inc
Responsible party
Sponsor
First posted
Sep 26, 2025
Start date
Sep 23, 2025
Primary completion
Sep 29, 2027 (estimated)
Completion
Sep 29, 2027 (estimated)
Last update
Apr 14, 2026

Study contacts

CEO
Contact
yingfeng.huang@cytocares.com
+86-021-50582090

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312

Start the discussion